Abstract
Clinical providers may underestimate the role of management of diseases that can occur with obesity, termed co-morbid conditions, distinct from disease that arise as a result of obesity, co-morbidities. Many of these conditions are associated with iatrogenic weight gain, and can interfere with weight loss outcomes in children and adolescents with obesity. Management of co-morbid conditions, and thoughtful selection of medications associated with weight neutrality or weight loss may increase the effectiveness of obesity treatment strategies. The aim of this commentary is to summarize the literature and discuss considerations for obesity treatment in the context of the more complicated patient, which often requires strategic management of co-morbid conditions and minimizing iatrogenic weight gain.
| Original language | English (US) |
|---|---|
| Article number | e12417 |
| Journal | Clinical obesity |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2021 |
Bibliographical note
Funding Information:Joseph A. Skelton, Brooke Sweeney and Aaron S. Kelly conceived and drafted the paper. Joseph A. Skelton, Brooke Sweeney, Christine B. San Giovanni and Aaron S. Kelly were involved in in writing sections of the paper. Joseph A. Skelton, Brooke Sweeney, Christine B. San Giovanni, Megan M. Kelsey and Aaron S. Kelly were involved in final writing and editing of the paper, and had final approval of the submitted and published versions.
Publisher Copyright:
© 2020 World Obesity Federation
Keywords
- medication
- obesity
- paediatric
- review
- treatment
